Correlation Between Edesa Biotech and SAB Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Edesa Biotech and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edesa Biotech and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Edesa Biotech and SAB Biotherapeutics, you can compare the effects of market volatilities on Edesa Biotech and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edesa Biotech with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edesa Biotech and SAB Biotherapeutics.
Diversification Opportunities for Edesa Biotech and SAB Biotherapeutics
-0.79 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Edesa and SAB is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Edesa Biotech and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Edesa Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edesa Biotech are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Edesa Biotech i.e., Edesa Biotech and SAB Biotherapeutics go up and down completely randomly.
Pair Corralation between Edesa Biotech and SAB Biotherapeutics
Given the investment horizon of 90 days Edesa Biotech is expected to under-perform the SAB Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Edesa Biotech is 35.33 times less risky than SAB Biotherapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The SAB Biotherapeutics is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest 4.71 in SAB Biotherapeutics on August 24, 2024 and sell it today you would earn a total of 1.98 from holding SAB Biotherapeutics or generate 42.04% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 73.6% |
| Values | Daily Returns |
Edesa Biotech vs. SAB Biotherapeutics
Performance |
| Timeline |
| Edesa Biotech |
| SAB Biotherapeutics |
Edesa Biotech and SAB Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Edesa Biotech and SAB Biotherapeutics
The main advantage of trading using opposite Edesa Biotech and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edesa Biotech position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.| Edesa Biotech vs. SAB Biotherapeutics | Edesa Biotech vs. Senti Biosciences | Edesa Biotech vs. Cingulate | Edesa Biotech vs. Neurobo Pharmaceuticals |
| SAB Biotherapeutics vs. Lyra Therapeutics | SAB Biotherapeutics vs. Hookipa Pharma | SAB Biotherapeutics vs. Cingulate Warrants | SAB Biotherapeutics vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |